-
公开(公告)号：US08318705B2
公开(公告)日：2012-11-27
申请号：US12437512
申请日：2009-05-07
CPC分类号： C07C207/00 , C07C207/04 , C07C255/19 , C07D211/44 , C07D211/58 , C07D309/10 , C07D309/14 , C07D333/42 , C07D405/12 , C07D405/14 , C07D407/12 , C07D451/10 , C07F9/117 , C07F9/58 , C07F9/59
摘要： The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
摘要翻译： 本发明涉及在生理条件下给予硝酰基（HNO）的羟基亚硝基化合物的羧酸和磷酸酯的亚硝基衍生物。 本发明的化合物和组合物可用于治疗和/或预防对硝酰病毒治疗（包括心力衰竭，局部缺血/再灌注损伤和癌症）有反应的疾病或病症的发作和/或发展。
-
公开(公告)号：US20120202806A1
公开(公告)日：2012-08-09
申请号：US13391712
申请日：2010-08-31
申请人： Franz Dürrenberger , Susanna Burckhardt , Peter O. Geisser , Wilm Buhr , Felix Funk , Julia M. Bainbridge , Vincent A. Corden , Stephen M. Courtney , Tara Davenport , Stefan Jaeger , Mark P. Ridgill , Mark Slack , Christopher J. Yarnold , Wei Tsung Yau
发明人： Franz Dürrenberger , Susanna Burckhardt , Peter O. Geisser , Wilm Buhr , Felix Funk , Julia M. Bainbridge , Vincent A. Corden , Stephen M. Courtney , Tara Davenport , Stefan Jaeger , Mark P. Ridgill , Mark Slack , Christopher J. Yarnold , Wei Tsung Yau
IPC分类号： A61K31/5377 , A61P3/02 , A61P7/06 , A61K31/506
CPC分类号： C07D401/04 , C07D239/47 , C07D251/18 , C07D251/66 , C07D401/14 , C07D403/04
摘要： The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
摘要翻译： 本发明涉及新的hepcidin拮抗剂，含有它们的药物组合物及其作为药物的用途，特别是用于治疗铁代谢紊乱，特别是铁缺乏症和贫血，特别是与慢性炎性疾病相关的贫血 （ACD：慢性病贫血和AI：炎症性贫血）。
-
3.发明申请公开(公告)号：US20090281062A1
公开(公告)日：2009-11-12
申请号：US12437512
申请日：2009-05-07
IPC分类号： A61K31/45 , C07D211/58 , C07C205/01 , C07D309/10 , C07D405/12 , A61K31/35 , A61K31/225 , A61K31/661 , A61K31/4433 , A61K31/444 , A61P9/00 , A61P35/00
CPC分类号： C07C207/00 , C07C207/04 , C07C255/19 , C07D211/44 , C07D211/58 , C07D309/10 , C07D309/14 , C07D333/42 , C07D405/12 , C07D405/14 , C07D407/12 , C07D451/10 , C07F9/117 , C07F9/58 , C07F9/59
摘要： The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
摘要翻译： 本发明涉及在生理条件下给予硝酰基（HNO）的羟基亚硝基化合物的羧酸和磷酸酯的亚硝基衍生物。 本发明的化合物和组合物可用于治疗和/或预防对硝酰病毒治疗（包括心力衰竭，局部缺血/再灌注损伤和癌症）有反应的疾病或病症的发作和/或发展。
-
公开(公告)号：US20120214803A1
公开(公告)日：2012-08-23
申请号：US13364566
申请日：2012-02-02
申请人： Wilm Buhr , Susanna Burckhardt , Franz Dürrenberger , Felix Funk , Peter O. Geisser , Vincent A. Corden , Stephen M. Courtney , Graham Dawson , Tara Davenport , Mark Slack , Mark P. Ridgill , Chrostopher J. Yarnold , Susan Boyce , Albertus A. Ellenbroek
发明人： Wilm Buhr , Susanna Burckhardt , Franz Dürrenberger , Felix Funk , Peter O. Geisser , Vincent A. Corden , Stephen M. Courtney , Graham Dawson , Tara Davenport , Mark Slack , Mark P. Ridgill , Chrostopher J. Yarnold , Susan Boyce , Albertus A. Ellenbroek
IPC分类号： A61K31/542 , C07D215/40 , C07D215/50 , C07D401/12 , C07D215/46 , A61P7/06 , A61K31/4706 , A61K31/4709 , A61K31/549 , A61K31/497 , A61P3/00 , C07D513/04 , C07D215/42
CPC分类号： C07D513/04 , A61K45/06 , C07D215/40 , C07D215/42 , C07D215/46 , C07D215/50 , C07D333/34 , C07D401/12 , C07D409/12 , C07D417/12
摘要： The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
摘要翻译： 本发明涉及新型的铁调素拮抗剂，包含它们的药物组合物及其作为用于治疗铁代谢紊乱的药物的用途，特别是铁缺乏症和贫血，特别是与慢性炎症有关的贫血 疾病
-
公开(公告)号：US20120214798A1
公开(公告)日：2012-08-23
申请号：US13394201
申请日：2010-09-06
申请人： Franz Dürrenberger , Susanna Burckhardt , Wilm Buhr , Peter O. Geisser , Felix Funk , Vincent A. Corden , Stephen M. Courtney , Tara Davenport , Stefan Jaeger , Mark P. Ridgill , Mark Slack , Christopher J. Yarnold , Wei Tsung Yau
发明人： Franz Dürrenberger , Susanna Burckhardt , Wilm Buhr , Peter O. Geisser , Felix Funk , Vincent A. Corden , Stephen M. Courtney , Tara Davenport , Stefan Jaeger , Mark P. Ridgill , Mark Slack , Christopher J. Yarnold , Wei Tsung Yau
IPC分类号： A61K31/497 , A61K31/5377 , A61P3/02 , A61K31/445 , A61K31/551 , A61K31/496 , A61K31/4545
CPC分类号： C07D401/12 , C07D211/14 , C07D211/58 , C07D211/62 , C07D213/38 , C07D239/42 , C07D241/20 , C07D295/13 , C07D307/24 , C07D405/12 , C07D405/14 , C07D409/12
摘要： The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
摘要翻译： 本发明涉及式（I）的新颖的铁调素拮抗剂，包含它们的药物组合物及其作为药物的用途，特别是用于治疗铁代谢紊乱，特别是铁缺乏症和疾病，特别是贫血 与慢性炎性疾病有关（ACD：慢性病贫血和AI：炎症性贫血）。
-
公开(公告)号：US20120196853A1
公开(公告)日：2012-08-02
申请号：US13390785
申请日：2010-08-19
申请人： Franz Dürrenberger , Susanna Burckhardt , Peter O. Geisser , Wilm Buhr , Felix Funk , Vincent A. Corden , Tara Davenport , Stefan Jaeger , Mark Slack , Christopher J. Yarnold , Wei Tsung Yau , Stephen M. Courtney
发明人： Franz Dürrenberger , Susanna Burckhardt , Peter O. Geisser , Wilm Buhr , Felix Funk , Vincent A. Corden , Tara Davenport , Stefan Jaeger , Mark Slack , Christopher J. Yarnold , Wei Tsung Yau , Stephen M. Courtney
IPC分类号： A61K31/5377 , A61K31/496 , A61P3/00 , A61P7/06 , A61P19/02 , A61P13/12 , A61P9/00 , A61P29/00 , A61P19/04 , A61P1/00 , A61K31/4709 , A61P35/00
CPC分类号： C07D215/28 , C07D215/26 , C07D215/32 , C07D401/06 , C07D401/14 , C07D405/06 , C07D409/06
摘要： The present invention relates to novel hepcidin antagonists of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
摘要翻译： 本发明涉及通式（I）的新型铁调素拮抗剂，包含它们的药物组合物及其作为药物的用途，特别是用于治疗铁代谢紊乱，特别是铁缺乏症和厌食症 与慢性炎症性疾病有关的特异性厌食症（ACD：慢性疾病和AI：炎症性贫血）。
-
7.发明申请TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF 审中-公开转谷氨酰胺酶TG2抑制剂，药物组合物及其使用方法公开(公告)号：US20150232420A1
公开(公告)日：2015-08-20
申请号：US14429288
申请日：2013-09-19
申请人： Celia DOMINGUEZ , Michael PRIME , Richard MARSTON , Frederick A. BROOKFIELD , Stephen M. COURTNEY , Douglas MACDONALD , John WITYAK , Christopher John YARNOLD , Darshan VAIDYA
发明人： Celia Dominguez , Michael Prime , Richard Marston , Frederick A. Brookfield , Stephen M. Courtney , Douglas Macdonald , John Wityak , Christopher John Yarnold , Darshan Vaidya
IPC分类号： C07C271/22 , C07D207/06 , C07D213/74 , C07D205/04 , C07D211/08 , C07D295/185 , C07D223/04
CPC分类号： C07C271/22 , C07D205/04 , C07D207/06 , C07D207/16 , C07D211/08 , C07D211/16 , C07D213/72 , C07D213/74 , C07D223/04 , C07D277/42 , C07D295/18 , C07D295/185 , C07D309/08 , C07D401/12
摘要： Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.
摘要翻译： 本文提供了某些化合物和药学上可接受的盐。 还提供了包含至少一种化合物或其药学上可接受的盐的药物组合物和一种或多种药学上可接受的载体。 描述了治疗患有某种疾病状态的患者对抑制转谷氨酰胺酶TG2活性有反应的方法。 这些疾病状态包括神经变性疾病如亨廷顿病。 还描述了治疗方法，包括给予至少一种化合物或其药学上可接受的盐作为单一活性剂，或者与一种或多种其它治疗剂组合施用至少一种化合物或其药学上可接受的盐。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.025 秒)
